Home
Journal Information
About
Aims and Scope
Contacts and Editorial Office
Editorial Board
Editor in Chief
Publisher
Conflicts of Interest
Editorial Policies
Publication Ethics
Nickan Research Institute policy
DISCLAIMER
Open Access
Journal Issues
Current Issue
In Press
Archive
Guidelines
For Authors
For Authors-New
For Reviewers
Peer Review Process in JRIP
Peer Review Process flowchart in JRIP
Authors agreement form
Checklist for review
Editorial Workflow
Publication Ethics and Malpractice Statement
Human and animal right
Informed Consent
Create Account
Login
Please don't use dangerous characters
Title
Author
Abstract
Keywords
First Name
Last Name
Search
eISSN
:
2345-2781
Submit Your Paper
Editorial Board
Aims and Scope
Publisher
Publication Fee
Contact Us
Archive
Indexing Information
Member of
Follower of
2024, Vol 13, No. 3
×
Journal of Renal Injury Prevention
Chief Editor: Azar Baradaran
Review
1. Late onset renal failure from angiotensin blockade (LORFFAB) and the syndrome of rapid onset endstage renal disease (SORO-ESRD) revisited – Two case reports from Mayo Clinic Health System, Northwestern Wisconsin, USA; a review paper
Macaulay Amechi Chukwukadibia Onuigbo*, Eileen Samuel, Nneoma Agbasi
J Renal Inj Prev
. 2018;7(2): 58-63.
doi:
10.15171/jrip.2018.15
Scopus ID:
85044750743
Article
PDF
XML
Cited By:
0
0
×
Late onset renal failure from angiotensin blockade (LORFFAB) and the syndrome of rapid onset endstage renal disease (SORO-ESRD) revisited – Two case reports from Mayo Clinic Health System, Northwestern Wisconsin, USA; a review paper
Mini-Review
2. Benefits and risks of dual inhibition of the renin– angiotensin aldosterone system for kidney disease
Nader Nourimajalan*
, Ahmad Shajari
, Sarasadat Moghadasimousavi
J Renal Inj Prev
. 2022;11(2): e31969.
doi:
10.34172/jrip.2022.31969
Scopus ID:
85130368722
Article
PDF
XML
Cited By:
0
0
×
Benefits and risks of dual inhibition of the renin– angiotensin aldosterone system for kidney disease
